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Avicin D Selectively Induces Apoptosis and
Downregulates p-STAT-3, bcl-2, and Survivin in
Cutaneous T-Cell Lymphoma Cells
Chunlei Zhang1, Baoqiang Li1, Amos S. Gaikwad2, Valsala Haridas3, Zhixiang Xu3, Jordan U. Gutterman3
and Madeleine Duvic1
Avicin D, a natural triterpenoid saponin, inhibits cell growth and induces apoptosis in transformed tumor cell
lines in vitro and mouse skin carcinogenesis models in vivo. To investigate the anti-tumor effects of avicin D in
cutaneous T-cell lymphomas (CTCL), we compared three CTCL cell lines and Se´zary cells from three Se´zary
syndrome (SS) patients with normal CD4þ and activated CD4þ T cells from three healthy donors. Avicin D at
0.5–5 mgml1 induced apoptosis in a time- and dose-dependent manner in three cell lines: MJ (0.2 to 13% and
0.6–37%), Hut78 (2–39% and 3–53%), and HH (13–83% and 44–89%) at 24 and 48 hours, respectively. Avicin D at
0.5–5 mgml1 for 48 hours caused more apoptosis in patients’ Se´zary cells than in healthy donors’ CD4þ T cells
and activated CD4þ T cells. The general caspase inhibitor Z-VAD-FMK and caspase-3 inhibitor Z-DEVD-FMK
decreased avicin D-induced apoptosis in CTCL cells. Caspase-3 was activated and poly (ADP-ribose) polymerase
was cleaved after avicin D treatment. Avicin D did not change the expression of signal transducer and activator
of transcription-3 (STAT-3) but decreased phospho-signal transducer and activator of transcription-3 (p-STAT-3)
protein levels in all three cell lines and two patients’ Se´zary cells. Avicin D also decreased expression of the
inhibitor of apoptosis protein survivin, the anti-apoptotic protein bcl-2, but not the pro-apoptotic protein bax in
these CTCL cells. In summary, avicin D selectively induced apoptosis, inhibited STAT-3 activation, and decreased
apoptosis inhibitors (bcl-2 and survivin) in CTCL cell lines and SS patients’ Se´zary cells. Our findings underlie
the therapeutic potential of avicin D in patients with SS.
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INTRODUCTION
Cutaneous T-cell lymphomas (CTCL) are extranodal non-
Hodgkin’s lymphomas with pleomorphic skin lesions and
distinct T-cell markers. Mycosis fungoides (MF), the most
common and indolent form of CTCL, is characterized by
epidermotropic and malignant CD4þCD45ROþCLAþ
CCRþ helper/memory T cells, which may lack CD7 and/or
CD26 expression. MF may evolve into a leukemic variant,
Se´zary syndrome (SS), or may transform to a large-cell
lymphoma expressing CD30þ in some cases (Duvic and
Cather, 2000; Kim et al., 2005). There are a limited number
of Food and Drug Administration (FDA)-approved therapeutic
modalities available to treat patients with MF/SS, including
topical and oral bexarotene (Duvic et al., 2001a, b),
intravenous denileukin diftitox (Olsen et al., 2001), photo-
pheresis (Zic, 2003), and vorinostat (Duvic et al., 2007; Olsen
et al., 2007). However, a number of non-approved agents are
commonly used as a standard of care and include topical
steroids and mustargen, phototherapy, IFNs, and chemo-
therapy (Duvic and Cather, 2000). Patients with refractory
or transformed MF and SS have a poor prognosis and therapy
is usually palliative. Alternative or complementary therapies,
especially for advanced MF/SS, are needed.
Avicins are a family of natural triterpenoid saponins
derived from the Cactus plant Acacia victoriae found in
Australia’s deserts (Jayatilake et al., 2003). In vitro, avicins
inhibit cell growth and induce apoptosis in leukemia and
epithelial cancer cell lines (Haridas et al., 2001a, b; Mujoo
et al., 2001). In a mouse skin carcinogenesis model, avicins
have been shown to suppress both initiation and promotion
phases of chemical carcinogenesis, as well as UV light B
damage with resultant suppression of oxidative DNA and
lipid damage (Hanausek et al., 2001; Haridas et al., 2004).
Avicins have also reported to induce apoptosis by affecting
mitochondrial function and activating the intrinsic caspase
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Avicins target and close the voltage-dependent anion
channel, subsequently leading to lower cell energy meta-
bolism and triggering cell apoptosis by permeabilization of
the outer mitochondrial membrane and release of cyto-
chrome c (Lemeshko et al., 2006; Haridas et al., 2007).
Avicins also suppress multiple pro-inflammatory components
of the innate immune system, including the transcriptional
factor NF-kB (Haridas et al., 2001a, b), the phosphoinositide-
3 kinase/AKT signaling pathway (Mujoo et al., 2001), as well
as heat shock proteins (Gaikwad et al., 2005).
In this study, we evaluated the anti-tumor effects of
avicin D on induction of apoptosis and modulation of
signal transducer and activator of transcription-3 (STAT-3)
and apoptosis-related proteins in CTCL cell lines and
patients’ Se´zary cells. Our data suggest that selective
induction of tumor T-cell apoptosis, inhibition of STAT-3
activation, and downregulation of bcl-2 and survivin underlie
the therapeutic potential of avicin D in patients with SS.
RESULTS
Avicin D treatment inhibited cell growth in CTCL cell lines
To determine whether avicin D inhibits CTCL cell growth,
MJ, Hut78, and HH cells were treated with or without
0.5, 1, 2, and 5 mgml1 avicin D for 24 and 48 hours, and
their viability was evaluated by CellTiter 96 AQueous
One Solution Cell Proliferation Assay. As the concentrations
of avicin D increased from 0.5 to 5 mgml1, HH cell growth
was inhibited from 0 to 81% and from 24 to 88% at 24
and 48 hours, respectively, in a dose- and a time-dependent
manner compared with vehicle control (n¼3, Po0.05).
Similar results were also seen in MJ and Hut78 cell lines;
however, MJ and Hut78 cells were less sensitive than HH
cells to avicin D in inhibiting cell growth (Figure 1).
Avicin D treatment induced apoptosis in CTCL cell lines
To determine whether the growth inhibition of CTCL cells by
avicin D results from apoptosis, MJ, Hut78, and HH cell lines
were treated with or without 0.5, 1, 2, and 5 mgml1 avicin D
for 24 and 48 hours. As the avicin D concentration increased
from 0.5 to 5 mgml1, the number of HH cells staining
for annexin V increased from 13 to 83% and 44 to 89% at 24
and 48 hours, respectively, in a dose- and time-dependent
manner compared with vehicle control (n¼3; Po0.05).
Again, similar results were also seen in MJ and Hut78 cell
lines; however, MJ and Hut78 cells were less sensitive than
HH cells to avicin D in inducing apoptosis (Figure 2).
Avicin D treatment selectively induced apoptosis
of SS patients’ Se´zary cells
To confirm the results from cell lines, we also tested the
pro-apoptotic effect of avicin D on primary Se´zary cells
from three SS patients who had 95–98% of circulating
CD4þCD26 T cells compared with normal CD4þ T cells
and activated CD4þ T cells from three normal donors
(Table 1). As the avicin D concentration increased from 0.5 to
5 mgml1, the number of SS patients’ Se´zary cells stained for
annexin V increased from 5.7 to 33% at 48 hours compared
with vehicle control. As the avicin D concentration increased
from 0.5 to 5 mgml1, the number of healthy donors’ CD4þ
T cells and activated CD4þ T cells stained for annexin V
increased from 0.9 to 2% and 0.2 to 5.8% at 48 hours
compared with vehicle control, respectively. Thus, avicin D
induced more apoptosis in SS patients’ Se´zary cells than in
healthy donors’ controls (Po0.05) (see Table 1). The results
suggest that avicin D was selective in inducing apoptosis of
SS patients’ Se´zary cells relative to healthy donors’ controls.
Avicin D-induced apoptosis was dependent on caspase-3 in
CTCL cells
Caspase-3 is a key downstream target for both the intrinsic
and extrinsic apoptosis pathways (Porter and Ja¨nicke, 1999).
To determine whether caspase-3 activation is involved in
avicin D-induced apoptosis, we examined the effects of
the general caspase inhibitor Z-VAD-FMK and caspase-3
inhibitor Z-DEVD-FMK in CTCL cells. Both Z-VAD-FMK and
Z-DEVD-FMK decreased avicin D-induced apoptosis in three
CTCL cell lines and one patient’s Se´zary cells (Figure 3).
Furthermore, we checked the expression of pro-caspase-3,
cleaved caspase-3, and poly (ADP-ribose) polymerase (PARP)
4
3
2
1
0
24 hours 48 hours 24 hours 48 hours 24 hours 48 hours
O
D4
90
4
3
2
1
0
O
D4
90
4
3
2
1
0
O
D4
90
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗ ∗
∗
MJ Hut78 HH
Control 0.5 μg ml–1 1 μg ml–1 2 μg ml–1 5 μg ml–1
Figure 1. Avicin D treatment inhibited cell growth of CTCL cell lines. Cells (5 104) were aliquoted into a 96-well culture plate and grown in medium with
or without 0.5, 1, 2, and 5 mgml1 avicin D for 24 and 48 hours. Cell viability was determined by comparing untreated control (H2O) to treated groups
with the CellTiter 96 AQueous One Solution Cell Proliferation Assay performed in triplicate. Each point represented mean±SD of triplicate determinations.
*represent values significantly different from controls (n¼3; Po0.05).
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proteins in three CTCL cell lines (MJ, Hut78, and HH) and
two SS patients’ Se´zary cells compared with healthy donors’
CD4þ T cells. Western blotting showed that avicin D
treatment activated capase-3 and cleaved PARP as deter-
mined by the appearance of cleaved 17- and 19-kDa and 85-
kDa fragments in CTCL cell lines and patients’ Se´zary cells
but not in healthy donors’ CD4þ T cells, respectively
(Figure 4).
Avicin D treatment modulated apoptosis-associated proteins
in CTCL cells
Constitutive activation of STAT-3 has been demonstrated to
contribute to oncogenesis by stimulating cell proliferation
and preventing apoptosis in CTCL (Nielsen et al., 1997;
Eriksen et al., 2001; Sommer et al., 2004). To determine
whether STAT-3 signaling and other apoptosis-related
proteins are involved in avicin D-induced apoptosis, we
examined the expression of STAT-3/phospho-signal trans-
ducer and activator of transcription-3 (p-STAT-3), bcl-2/bax,
and survivin in three CTCL cell lines (MJ, Hut78, and HH)
and two patients’ Se´zary cells compared with healthy donors’
CD4þ T cells. Western blotting showed that p-STAT-3
protein expressed and decreased in three cell lines and
two patients’ Se´zary cells but not in healthy donors’ CD4þ
T cells after avicin D treatment. Avicin D treatment did not
significantly change protein levels of STAT-3 in all cell lines,
patients’ Se´zary cells, and healthy donors’ CD4þ T cells
after avicin D treatment. The levels of pro-apoptotic protein
bax remained constant in all cell lines, patients’ Se´zary cells,
and healthy donors’ CD4þ T cells after avicin D treatment.
However, expression of the anti-apoptotic protein bcl-2
decreased after avicin D treatment in these cell lines and
patients’ Se´zary cells, but did not significantly change in
healthy donors’ CD4þ T cells. Moreover, avicin D treatment
decreased protein levels of survivin in these cell lines and
patients’ Se´zary cells. Survivin was not observed in healthy
donors’ CD4þ T cells without or with avicin D treatment
(Figure 4).
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Figure 2. Avicin D treatment induced apoptosis in CTCL cell lines. Cells (1 106) were treated with or without 0.5, 1, 2 and 5 mgml1 avicin D for
24 and 48hours. Annexin V binding was carried out with the Annexin V-FITC Detection Kit. (a) avicin D induced a concentration- and time-dependent
apoptosis in the HH cell line. The lower right quadrant showed annexin VþPI cells. The upper right quadrant showed annexin VþPIþ cells. (b) Each bar
represented the percentage (mean±SD of triplicate determinations) of both annexin VþPI and annexin VþPIþ cells. *represent values significantly
different from control (n¼3; Po0.05).
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The autophagy inhibitor protected avicin D-induced cell
death in CTCL cells
Because general caspase inhibitor Z-VAD-FMK and caspase-
3 inhibitor Z-DEVD-FMK only partially decreased avicin
D-induced apoptosis in CTCL cells, we hypothesized that
avicin D may also induce a caspase-independent pro-
grammed cell death, such as autophagy. To test whether
avicin D induces autophagy, three CTCL cell lines (MJ,
Hut78, and HH) were pretreated with chloroquine (10 mM), an
inhibitor of autophagy (Xu et al., 2007), for 6 hours and then
incubated with avicin D (5 mM) for 48 hours. Our results
showed that CTCL cells pretreated with chloroquine had
improved cell viability (Figure 5a) and decreased cell death
(Figure 5b) relative to cells treated with avicin D alone,
suggesting that avicin D may also induce autophagy in CTCL
cells.
DISCUSSION
Apoptosis plays important roles in embryogenesis, aging,
and cancer cell survival (Webb et al., 1997). A major goal
in clinical cancer research is to discover compounds that
selectively induce apoptosis without adversely affecting
normal cell growth. The anti-tumor actions of many chemo-
therapeutic agents have been attributed to the induction of
apoptosis (Hickman, 1992). The most effective treatments for
MF/SS, such as phototherapy (Baron and Stevens, 2003),
photopheresis (Zic, 2003), bexarotene (Zhang et al., 2002),
and vorinostat (Zhang et al., 2005), induce apoptosis of
T cells. In this study, we show for the first time that avicin D,
a novel triterpenoid saponin, selectively causes apoptosis
of CTCL cell lines and patients’ Se´zary cells compared with
normal CD4þ and activated CD4þ T cells from healthy
donors. Furthermore, recent studies showed that avicin D
also induces autophagy, another type of programmed cell
death (Xu et al., 2007). Of interest, our preliminary data
revealed that CTCL cells pretreated with chloroquine, an
inhibitor of autophagy, had reduced cell death and improved
cell viability relative to cells treated with avicin D alone,
Table 1. Avicin D selectively induced apoptosis of SS patients’ Se´zary cells
1Apoptosis % (48h)
Concentrations (lg/ml)
Patient no. Age/gender Diagnosis CD4+CD26 (%) 0.5 1 2 5
1 76/F SS 98 11% 28% 31% 39%
2 51/F SS 95 2% 6% 13% 27%
3 69/F SS 96 4% 11% 22% 33%
Statistic analysis
Tumor CD4+ T cells (n=3) 5.7±4.7 15±11.5 22±9 33±6
Total (mean±SD) Tumor CD4+ T cells (n=3) 0.9±1.4 0.2±1.3 0.3±0.2 2±0.6
Activated CD4+ T cells (n=3) 0.2±0.9 1±0.7 2.3±0.8 5.8±0.8
P-value
Tumor CD4+ vs normal CD4+ P=0.08 P=0.09 P=0.01 P=0.0009
Tumor CD4+ vs activated CD4+ P=0.12 P=0.10 P=0.02 P=0.002
F, female; PI, propidium iodide; SS, Se´zary syndrome.
1Apoptosis was determined by flow cytometry analysis of annexin V/PI staining. The values represented the percentage of annexin V+PI and annexin V+PI+
binding from normal CD4+ T cells, activated CD4+ T cells, and SS patients’ Se´zary cells treated with different concentrations of avicin D compared with
vehicle control.
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Figure 3. Effect of caspase inhibitors on avicin D-induced apoptosis in CTCL
cells. Cells (1 106) were pretreated with or without 50 mM Z-VAD-FMK or
Z-DEAD-FMK for 2 hours, and then followed with 5mgml1 avicin D for
48 hours. Annexin V binding was carried out with the Annexin V-FITC
Detection Kit. (a) Z-VAD-FMK inhibited avicin D-induced apoptosis in
CTCL cells; (b) Z-DEAD-FMK inhibited avicin D-induced apoptosis in
CTCL cells. Each bar represented the percentage (mean±SD of triplicate
determinations) of both annexin VþPI and annexin VþPIþ cells.
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suggesting that avicin D may also induce autophagy in CTCL.
Further experiments for detecting autophagosomes are
needed to confirm our above observation in CTCL.
Avicins have been shown to induce apoptosis by affecting
mitochondrial function and activating caspase-3 in the
human T-cell leukemia Jurkat cell line (Haridas et al.,
2001a, b). Caspase-3 is a key component of apoptosis, is
activated in apoptotic cells, and cleaves cellular proteins,
including PARP (Porter and Ja¨nicke, 1999). Cleavage of PARP
is a hallmark of apoptosis induced by various anti-tumor
agents (Duriez and Shah, 1997). We have previously reported
that caspase-3 is activated and PARP is cleaved in apoptotic
CTCL cells after treatment with the retinoid X receptor (RXR)-
selective retinoid bexarotene (Zhang et al., 2002) and with
the histone deacetylase inhibitor vorinostat (Zhang et al.,
2005). Of interest, another triterpenoid compound, CDDO
(2-cyano-3-3, 12-dioxoolean-1, 9-dien-28-oic acid), also
induces T-cell apoptosis in CTCL cells in association with
activation of caspase-3 and cleavage of PARP (Zhang et al.,
2004). In this study, we show that general caspase inhibitor
Z-VAD-FMK and caspase-3 inhibitor Z-DEVD-FMK decrea-
sed avicin D-induced apoptosis in CTCL cells. Avicin D
treatment also activated caspase-3 and cleaved PARP in three
CTCL cell lines and patients’ Se´zary cells but not in healthy
donors’ CD4þ T cells. Thus, avicin D-induced apoptosis is at
least partially dependent on caspase-3 in CTCL cells.
To understand the mechanism of apoptosis induced
by avicin D, we examined the STAT-3 signaling pathway.
STAT-3 is activated by a wide variety of extracellular and
intracellular stimuli, including IL-2, IL-6, IL-7, IL-9, IL-10, and
IL-15, and by intracellular tyrosine kinases, such as src and
abl (Calo et al., 2003). After activation by phosphorylation,
STAT-3 proteins dimerize and translocate from cytoplasm to
the nucleus where they bind to specific DNA promoter
sequences and regulate gene expression (Calo et al., 2003).
Constitutive activation of STAT-3 contributes to oncogenesis
by stimulating cell proliferation and preventing apoptosis in
solid tumors and hematological malignancies, including
CTCL (Sommer et al., 2004; Turkson, 2004; Mitchell and
John, 2005). In particular, STAT-3 activation is possibly
involved in the neoplastic transformation of CTCL and may,
therefore, be a molecular target for therapeutic interven-
tions, especially for advanced patients (Sommer et al., 2004).
In this study, activation of STAT-3 was not observed in
healthy donors’ CD4þ T cells, which is consistent with the
previous report (van Kester et al., 2008). Furthermore, we
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Figure 4. Effect of avicin D on modulation of apoptosis-associated proteins in CTCL cell lines and patients’ Se´zary cells. Three cell lines (MJ, Hut78, and
HH), Se´zary cells from two SS patients, and normal CD4þ T cells from two healthy donors were treated with avicin D at 2 mgml1 for 24 hours. Cytoplasmic
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found that avicin D at concentrations causing apoptosis
decreased expression of p-STAT-3 (but not STAT-3) in
three CTCL cell lines and two patients’ Se´zary cells. To
our knowledge this is previously unreported. Thus, down-
regulation of p-STAT-3 protein may be involved in avicin
D-induced apoptosis of CTCL cells. However, the mecha-
nisms of reducing p-STAT-3 by avicin D remain to be
evaluated in CTCL.
The balance between bcl-2 and bax expression is
critical in controlling caspase activation by regulating the
release of cytochrome c from mitochondria (Manion and
Hockenbery, 2003). Bcl-2 expressed in CTCL cells may
increase survival and resistance of CTCL cells against
radiotherapy and extracorporeal photochemotherapy
(Osella-Aate et al., 2001; Breuckmann et al., 2002; Zhang
et al., 2003). In this study, we show that avicin D at concen-
trations causing apoptosis did not change pro-apoptotic
protein bax but decreased anti-apoptotic protein bcl-2 in
CTCL lines and patients’ Se´zary cells. Thus, alteration of the
bcl-2/bax ratio is likely to be involved in avicin D-induced
apoptosis of CTCL cells.
Survivin is a member of the inhibitor of apoptosis protein
family (Ambrosini et al., 1997). Survivin is not expressed
in normal adult tissues, but is abundantly expressed in
fetal tissues, transformed cell types, and a variety of human
tumors, including highly malignant non-Hodgkin’s lympho-
ma (Ambrosini et al., 1997; Adida et al., 1998). In vitro,
survivin is not expressed in resting T cells but expressed
in activated T lymphocytes, and its expression correlates with
apoptosis resistance after lymphocyte activation (Kornacker
et al., 2001). Survivin suppresses caspase activity and
protects cells from apoptosis induced by a variety of agents
(LaCasse et al., 1998). We previously demonstrated that
CTCL cells express survivin protein, and its expression
decreases after bexarotene treatment (Zhang et al., 2002).
In this study, our results show that survivin was expressed
in SS patients’ Se´zary cells but not in healthy donors’ CD4þ
T cells, which is consistent with the previous studies
(Kornacker et al., 2001; Sors et al., 2008). Avicin D treatment
decreased the protein levels of survivin in CTCL cell lines and
in patients’ Se´zary cells. This suggests that downregulation
of survivin may be involved in caspase-3 activation in avicin
D-induced apoptosis of CTCL cells.
In conclusion, avicin D selectively induced apoptosis of
CTCL cell lines and Se´zary cells from SS patients compared
with normal CD4þ and activated CD4þ T cells from
healthy donors. Avicin D-induced apoptosis was at least
partially dependent on caspase-3 and was associated with
downregulation of p-STAT-3 and anti-apoptotic proteins
(bcl-2 and survivin). Although avicin D has not been used
in patients yet, two other triterpenoid compounds (CDDO
and CDDO-Me) are currently well tolerated in phase I
clinical trials for the treatment of leukemia and solid tumors
(Hong et al., 2007; Liby et al., 2007). Our findings provide a
rationale for studying avicin D in patients with SS. Further
experiments are needed to profile toxicity of avicin D and to
better clarify the molecular details of anti-tumor effect for
pre-clinical development.
MATERIALS AND METHODS
Reagents
Avicin D was isolated from the seedpods of the Australian desert
plant, Acacia victoriae (Jayatilake et al., 2003). Avicin D was
dissolved in distilled water to a stock concentration of 1mgml1 and
stored at 4 1C. Serial dilutions (0.5, 1, 2, and 5 mgml1) were freshly
made in RPMI 1640 medium (Sigma-Aldrich, St Louis, MO). Z-VAD-
FMK and Z-DEVD-FMK were purchased from R&D Systems
(Minneapolis, MN), dissolved in DMSO to a stock concentration
of 20mM, and stored at 80 1C. Monoclonal mouse anti-CD3
(clone UCHT1) was purchased form BioLegend (San Diego, CA).
Chloroquine was purchased from Sigma-Aldrich.
Cells and cell culture
The human CTCL cell lines MJ (G11), Hut78, and HH, obtained from
American Type Culture Collection (Rockville, MD), were derived
from peripheral blood of patients with MF, SS, and non-MF/SS
aggressive CTCL, respectively (Gootenberg et al., 1981; Popovic
et al., 1983; Starkebaum et al., 1991). Samples of peripheral blood
were obtained for in vitro studies from three healthy donors and
three SS patients with 95–98% circulating CD4þCD26 tumor T
cells (Bernengo et al., 2001) (see Table 1). Samples were obtained
during routine diagnostic assessments. The institutional review
board of MD Anderson Cancer Center approved this study and
the participants gave written informed consent. This study was
conducted according to the Declaration of Helsinki Principles.
Peripheral blood mononuclear cells from these healthy donors
and patients were isolated by Vacutainer CPT (Becton Dickinson,
San Jose, CA). CD4þ T cells were sorted by Human CD4 T Cell
Enrichment Cocktail (StemCell Technologies, Vancouver, BC,
Canada) according to the manufacturer’s instructions. CD4þ T-cell
activation was performed using anti-CD3 antibody (clone UCHL1)
as previously described (Ni et al., 2005). Cells were grown in RPMI
1640 medium (Sigma Chemical Co., St Louis, MO) supplemented
with 10% heat-inactivated fetal bovine serum (HyClone Labora-
tories, Logan, UT), 2mM 4-(2-hydroxyethyl)-1-piperazineethanesul-
fonic acid (HEPES), and 1% penicillin–streptomycin in a humidified
atmosphere with 5% CO2 at 37 1C.
Cell viability
Cell viability was measured by CellTiter 96 AQueous One Solution
Cell Proliferation Assay (Goodwin et al., 1995) according to the
manufacturer’s instructions (Promega, Madison, WI). Aliquots of
5 104 cells per well were distributed in 96-well microplates
(Falcon, Franklin Lakes, NJ) in 100ml of medium and incubated with
0.5, 1, 2, and 5mgml1 avicin D for 24 and 48 hours, then 20 ml of
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium, inner salt was added to each well and
incubated for an additional 4 hours. The relative cell viability
was determined at 490 nm using 96-well plate reader. Each
experiment was performed in triplicate, and repeated a minimum
of three times.
Annexin V binding staining
Analysis of annexin V binding was carried out with an Annexin
V-FITC Detection Kit I (Pharmingen, San Diego, CA) according to the
manufacturer’s instructions. Briefly, three cell lines (MJ, Hut78, and
HH), CD4þ T cells, activated CD4þ T cells from three healthy
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donors, and Se´zary cells from three SS patients were incubated with
or without avicin D (0.5, 1, 2, and 5 mgml1), Z-VAD-FMK (50 mM),
Z-DEVD-FMK (50 mM), or chloroquine (10 mM) for the indicated time
courses. Cells were collected, washed twice with cold phosphate-
buffered saline, and centrifuged at 1,500 r.p.m. for 5minutes. Cells
were resuspended in 1 binding buffer at a concentration of
1 106 cellsml1, 100 ml of the solution was transferred to a 5-ml
culture tube, and 5 ml of annexin V-FITC and 5 ml of propidium
iodide (PI) were added. Cells were gently vortexed, and incubated
for 15minutes at room temperature in the dark. Finally, 400 ml of
1 binding buffer was added to each tube, and samples were
analyzed by FACScan flow cytometer (Becton Dickinson). For each
sample, 10,000 ungated events were acquired. Annexin VþPI cells
represent the early apoptotic populations and annexin VþPIþ cells
represent either late apoptotic or secondary necrotic populations.
Isolation of cytoplasmic and nuclear extracts
Isolation of proteins was conducted as previously described (Zhang
et al., 2002). Briefly, cells (5 106) were washed with ice-cold
phosphate-buffered saline, harvested into 1ml of phosphate-buffered
saline, pelleted in a 1.5-ml microcentrifuge tube, and suspended in
400ml of buffer A (10mM HEPES (pH 7.9), 10mM KCl, 1mM EDTA,
1mM EGTA (ethylene glycol bis(b-aminoethylether)-N,N,N0,N0,-
tetraacetic acid), 1mM dithiothreitol, and 1 protease inhibitor
cocktail ‘‘complete mini’’ (Roche, Indianapolis, IN)). After 20min-
utes incubation on ice, the mixture was treated with a 24-G syringe
for five times and then centrifuged briefly to obtain the cytoplasmic
supernatant. The nuclear pellet was resuspended in 40–80 ml of
buffer C (10mM HEPES (pH 7.9), 10mM KCl, 1mM EDTA, 1mM
EGTA, 1mM dithiothreitol, 10% glycerol, and 1 protease inhibitor
cocktail ‘‘complete mini’’ (Roche)) and incubated at 4 1C for
15minutes with shaking. Protein concentrations were determined
by the Bradford dye-binding protein assay (Bio-Rad, Richmond, CA)
using BSA as a standard.
Western blot analysis
Western blotting was performed as previously described (Zhang
et al., 2002). Briefly, cytoplasmic (10 mg) or nuclear (5mg) proteins
were subjected to SDS-PAGE (8–12%) electrophoresis and trans-
ferred onto nitrocellulose membranes (Schleicher & Schuell, Dasse,
Germany). The membranes were blocked in 3% powdered milk in
TBST (50mM Tris (pH 7.5), 150mM NaCl, 0.05% Tween 20) for
1 hour at room temperature, incubated with primary antibodies
overnight at 4 1C in 3% powdered milk in TBST, and washed
extensively with TBST. They were incubated with 1:5,000
peroxidase-conjugated anti-mouse or anti-rabbit secondary anti-
body (Jackson ImmunoResearch, West Grove, PA) for 1 hour at
room temperature. Monoclonal mouse anti-STAT-3 (1:1,000) anti-
body was obtained from BD Bioscience (San Diego, CA). Mono-
clonal mouse anti-bcl-2 (1:2,000), anti-survivin (1:500), anti-actin
(1:2,000), anti-caspase-3 (1:1,000), and anti-PARP (1:1,000) anti-
bodies were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). Polyclonal rabbit anti-bax (1:500) antibody was obtained from
Santa Cruz Biotechnology. Monoclonal mouse anti-phospho-STAT-3
(p-STAT-3) (1:1,000) and rabbit anti-cleaved caspse-3 (1:1,000)
antibodies were obtained from Cell Signaling (Beverly, MA).
Immunoreactive bands were visualized by enhanced chemi-
luminescence detection kit (Amersham, Buckinghamshire, UK),
and equivalent loading of proteins in each well was confirmed by
actin and Ponceau staining.
Statistical analysis
Statistical significance of differences observed in cell viability and
apoptosis in avicin D-treated cells compared with the untreated cells
was determined by using the Student’s t-test. Experiments were
repeated twice and carried out in triplicate. The minimum level of
significance was a Po0.05.
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